Cargando…

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()

Detalles Bibliográficos
Autores principales:	Aomar-Millán, Ismael Francisco, Salvatierra, Juan, Callejas-Rubio, José Luis, Raya-Álvarez, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier España, S.L.U. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219577/ https://www.ncbi.nlm.nih.gov/pubmed/35752586 http://dx.doi.org/10.1016/j.reumae.2022.06.001

Ejemplares similares

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Stredny, Coral M., et al.
Publicado: (2020)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Anakinra/tocilizumab: Primary biliary cholangitis: case report
Publicado: (2021)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Tratamiento y evolución del síndrome de tormenta de citoquinas asociados a infección por SARS-CoV-2 en pacientes octogenarios
por: Callejas Rubio, José Luis, et al.
Publicado: (2020)

Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Refractory Sweet Syndrome Treated with Anakinra
por: Shahid, Zainab, et al.
Publicado: (2019)

Dexametasona frente a metilprednisolona ajustada al peso en pacientes con neumonía moderada-grave por SARS-CoV-2
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
por: Arcani, Robin, et al.
Publicado: (2023)

Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection()
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Anakinra treatment for refractory cerebral autoinflammatory responses
por: Jang, Yoonhyuk, et al.
Publicado: (2022)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study
por: KÜÇÜKŞAHİN, Orhan, et al.
Publicado: (2022)

Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
por: Cure, Erkan, et al.
Publicado: (2021)

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
por: Muñoz-Jiménez, Alejandro, et al.
Publicado: (2021)

Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review
por: Prieto-Peña, Diana, et al.
Publicado: (2021)

Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Bhat, Chandrika S., et al.
Publicado: (2021)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis
por: Peng, Jingwen, et al.
Publicado: (2021)

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra
por: Angeletti, Andrea, et al.
Publicado: (2021)

The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response
por: Başaran, Seniha, et al.
Publicado: (2021)

Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra
por: Gambacorta, Alessandro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_herocgoph8ukem315aklpir93u